(Q33357713)

English

Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14630267%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14630267%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14630267%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

author name string

Gianni Fellin

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14630267%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Umberto Graffer

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14630267%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Francesco Valduga

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14630267%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Andrea Bolner

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14630267%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Lucio Luciani

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14630267%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Luigi Tomio

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14630267%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Enzo Galligioni

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14630267%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

language of work or name

0 references

publication date

1 December 2003

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14630267%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

International Journal of Radiation Oncology Biology Physics

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14630267%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

57

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14630267%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1310-1316

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14630267%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14630267%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Invasive bladder cancer: treatment strategies using transurethral surgery, chemotherapy and radiation therapy with selection for bladder conservation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900763-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900763-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900763-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900763-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900763-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900763-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900763-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900763-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900763-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900763-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900763-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900763-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900763-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900763-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900763-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900763-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900763-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine)

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900763-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900763-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900763-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0360-3016(03)00763-6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14630267%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14630267%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33357713&oldid=2049931220"